0 Bedömningar
ID

22331

Beskrivning

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Länk

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Nyckelord

Versioner (1)
  1. 2017-05-30 2017-05-30 -
Uppladdad den

30 maj 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

  • Senaste
  • Äldsta
  • Önskad
  • Senaste
    • Senaste
    • Äldsta
    • Önskad

    Inga kommentarer

    Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    Engelsk

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 Formulär  
    Concomitant Medication
    Beskrivning

    Concomitant Medication

    Alias
    UMLS CUI-1
    C2347852 (Concomitant Agent)
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    Beskrivning

    Concomitant agent

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C2347852 (Concomitant Agent)
    Concomitant Medication Changes
    Beskrivning

    Concomitant Medication Changes

    Alias
    UMLS CUI-1
    C2347852 (Concomitant Agent)
    Drug name (Trade Name preferred)
    Beskrivning

    Drug name

    Datatyp

    text

    Alias
    UMLS CUI [1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    SINGLE Dose/ Unit (e.g. 500mg)
    Beskrivning

    Single dose/Unit

    Datatyp

    float

    Alias
    UMLS CUI [1,1]
    C2826257 (Prior Medication Usage)
    UMLS CUI [1,2]
    C1960417 (Single dose characteristic)
    SNOMED
    426146003
    Frequency of this Dose (e.g. BID PRN)
    Beskrivning

    Frequency

    Datatyp

    text

    Alias
    UMLS CUI [1]
    C3476109 (Medication frequency)
    LOINC
    LP149758-7
    Route
    Beskrivning

    Concomitant Medication Route of Administration

    Datatyp

    text

    Alias
    UMLS CUI [1]
    C2826730 (Concomitant Medication Route of Administration)
    Indication
    Beskrivning

    Indication

    Datatyp

    text

    Alias
    UMLS CUI [1,1]
    C2347852 (Concomitant Agent)
    UMLS CUI [1,2]
    C3146298 (Indication)
    Start Date/Time
    Beskrivning

    Start Date Time

    Datatyp

    datetime

    Alias
    UMLS CUI [1]
    C2827019 (Substance Use Start Date Time)
    End Date/Time
    Beskrivning

    Stop Date

    Datatyp

    datetime

    Alias
    UMLS CUI [1,1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    UMLS CUI [1,2]
    C0806020 (End date)
    SNOMED
    454551000124105
    LOINC
    MTHU008302
    UMLS CUI [2,1]
    C0013227 (Pharmaceutical Preparations)
    SNOMED
    763158003
    LOINC
    LP100609-9
    UMLS CUI [2,2]
    C1522314 (End Time)
    SNOMED
    397898000
    Continuing at end of Study?
    Beskrivning

    Continuing at end of study

    Datatyp

    boolean

    Alias
    UMLS CUI [1]
    C1553904 (continuing therapy)
    Tillbaka till toppen

    Similar models

    Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

    1 Formulär
    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datatyp
    Alias
    Item Group
    Concomitant Medication
    C2347852 (UMLS CUI-1)
    Concomitant agent
    Item
    Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
    boolean
    C2347852 (UMLS CUI [1])
    Item Group
    Concomitant Medication Changes
    C2347852 (UMLS CUI-1)
    Drug name
    Item
    Drug name (Trade Name preferred)
    text
    C0013227 (UMLS CUI [1])
    Single dose/Unit
    Item
    SINGLE Dose/ Unit (e.g. 500mg)
    float
    C2826257 (UMLS CUI [1,1])
    C1960417 (UMLS CUI [1,2])
    Frequency
    Item
    Frequency of this Dose (e.g. BID PRN)
    text
    C3476109 (UMLS CUI [1])
    Concomitant Medication Route of Administration
    Item
    Route
    text
    C2826730 (UMLS CUI [1])
    Indication
    Item
    Indication
    text
    C2347852 (UMLS CUI [1,1])
    C3146298 (UMLS CUI [1,2])
    Start Date Time
    Item
    Start Date/Time
    datetime
    C2827019 (UMLS CUI [1])
    Stop Date
    Item
    End Date/Time
    datetime
    C0013227 (UMLS CUI [1,1])
    C0806020 (UMLS CUI [1,2])
    C0013227 (UMLS CUI [2,1])
    C1522314 (UMLS CUI [2,2])
    Continuing at end of study
    Item
    Continuing at end of Study?
    boolean
    C1553904 (UMLS CUI [1])
    Tillbaka till toppen 

    Hjälp

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial